Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy
Authors:
Open Access
- 22 October 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1433774
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has ushered in a new era for the treatment of multiple myeloma (MM). Numerous clinical studies, especially those involving B-cell maturation antigen (BCMA)-directed CAR-T, have shown remarkable efficacy in patients with relapsed or refractory multiple myeloma (R/R MM). However, a considerable number of patients still experience disease recurrence or progression after BCMA CAR-T treatment, which is attributed to various factors, including antigen escape, CAR-T manufacturing factors, T cell exhaustion, inhibitory effects of tumor microenvironment and impact of prior treatments. The scarcity of effective treatment options following post-CAR-T disease recurrence, coupled with the lack of well-established salvage regimens, leaves patients who do relapse facing a bleak prognosis. In recent years, some academic institutions have achieved certain results in salvage treatments of patients with relapse after BCMA CAR-T treatment through secondary infusion of BCMA CAR-T, changing to non-BCMA-directed CAR-T, double-target CAR-T, bispecific antibodies or other novel therapies. This review summarizes the mechanisms of resistance or relapse after BCMA CAR-T administration and the available data on current salvage treatments, hoping to provide ideas for optimizing clinical salvage therapies.Keywords
This publication has 125 references indexed in Scilit:
- Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myelomaCancer Medicine, 2023
- A second‐generation CD38‐CAR‐T cell for the treatment of multiple myelomaCancer Medicine, 2023
- Subsequent anti‐myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)‐T cell (HDS269B) treatment in patients with relapsed/refractory multiple myelomaAmerican Journal of Hematology, 2022
- Current state and next-generation CAR-T cells in multiple myelomaBlood Reviews, 2022
- Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myelomaCurrent Opinion in Immunology, 2021
- Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literatureCancer Immunology, Immunotherapy, 2021
- Mechanisms of response and resistance to CAR T cell therapiesCurrent Opinion in Immunology, 2021
- B‐cell maturation antigen‐specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectivesInternational Journal of Cancer, 2020
- Daratumumab in multiple myelomaCancer, 2019
- Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myelomaEBioMedicine, 2019